{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T21:10:48Z","timestamp":1776978648986,"version":"3.51.4"},"reference-count":26,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2022,6,21]]},"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1136\/ejhpharm-2021-003198","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T13:20:31Z","timestamp":1658236831000},"page":"135-142","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Short-term study on in-use stability of opened bevacizumab biosimilar PF-06439535 vials"],"prefix":"10.1136","volume":"31","author":[{"given":"Mona","family":"Abdel-Tawab","sequence":"first","affiliation":[{"name":"Central Laboratory of German Pharmacists, Eschborn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Wa\u00dfmuth","sequence":"additional","affiliation":[{"name":"Central Laboratory of German Pharmacists, Eschborn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Gegenfurtner","sequence":"additional","affiliation":[{"name":"Coriolis Pharma Research GmbH, Martinsried, Bayern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Hawe","sequence":"additional","affiliation":[{"name":"Coriolis Pharma Research GmbH, Martinsried, Bayern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H","family":"Schefe","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke M","family":"Strunz","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"W\u00fcbert","sequence":"additional","affiliation":[{"name":"Central Laboratory of German Pharmacists, Eschborn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"2025090703030493000_31.2.135.1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030083"},{"key":"2025090703030493000_31.2.135.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017"},{"key":"2025090703030493000_31.2.135.3","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.2.603"},{"key":"2025090703030493000_31.2.135.4","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A1987"},{"key":"2025090703030493000_31.2.135.5","doi-asserted-by":"publisher","DOI":"10.1177\/1758834010376301"},{"key":"2025090703030493000_31.2.135.6","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/IAE.0000000000002212","article-title":"Long-term physical stability, sterility, and anti-VEGF bioactivity of repackaged bevacizumab in 2-mL glass vials","volume":"39","author":"Peterson","year":"2019","journal-title":"Retina"},{"key":"2025090703030493000_31.2.135.7","unstructured":"European Medicines Agency (EMA) . Avastin summary of product characteristics [Internet], 2015. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/avastin-epar-product-information_en.pdf [Accessed 14 Jul 2022]."},{"key":"2025090703030493000_31.2.135.8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.2217\/fon-2018-0051","article-title":"Bevacizumab biosimilars: scientific justification for extrapolation of indications","volume":"14","author":"Melosky","year":"2018","journal-title":"Future Oncol"},{"key":"2025090703030493000_31.2.135.9","unstructured":"European Medicines Agency (EMA) . Biosimiar medicines: overview [Internet], 2019. Available: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/biosimilar-medicines-overview [Accessed 14 Jul 2022]."},{"key":"2025090703030493000_31.2.135.10","unstructured":"European Medicines Agency (EMA), European Commission . Biosimilars in the EU: information guide for healthcare professionals [Internet], 2019. Available: https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf [Accessed 14 Jul 2022]."},{"key":"2025090703030493000_31.2.135.11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.yrtph.2018.03.020","article-title":"Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab","volume":"95","author":"Peraza","year":"2018","journal-title":"Regul Toxicol Pharmacol"},{"key":"2025090703030493000_31.2.135.12","unstructured":"Grunder B , Costigan L , Johnson K . Characterization and similarity assessment of bevacizumab and a proposed biosimilar, Poster W5349. In: American Association of Pharmaceutical Scientists (AAPs) Annual Meeting and Exhibition. San Diego, CA, 2014."},{"key":"2025090703030493000_31.2.135.13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00280-016-3001-2","article-title":"A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers","volume":"77","author":"Knight","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025090703030493000_31.2.135.14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40259-019-00363-4","article-title":"PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin\u00ae), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study","volume":"33","author":"Reinmuth","year":"2019","journal-title":"BioDrugs"},{"key":"2025090703030493000_31.2.135.15","unstructured":"European Medicines Agency (EMA) . Zirabev (bevacizumab) EPAR \u2013 medicine overview [Internet], 2020. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zirabev [Accessed 14 Jul 2022]."},{"key":"2025090703030493000_31.2.135.16","unstructured":"European Medicines Agency (EMA) . Zirabev summary of product characteristics [Internet], 2021. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zirabev-epar-product-information_en.pdf [Accessed 14 Jul 2022]."},{"key":"2025090703030493000_31.2.135.17","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000225354.92444.7a"},{"key":"2025090703030493000_31.2.135.18","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2008.0043"},{"key":"2025090703030493000_31.2.135.19","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.139"},{"key":"2025090703030493000_31.2.135.20","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/eye.2015.28","article-title":"Storage stability of bevacizumab in polycarbonate and polypropylene syringes","volume":"29","author":"Khalili","year":"2015","journal-title":"Eye"},{"key":"2025090703030493000_31.2.135.21","unstructured":"European Medicines Agency (EMA) . Assessment report: Zirabev [Internet], 2018. Available: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zirabev-epar-public-assessment-report_en.pdf [Accessed 14 Jul 2022]."},{"key":"2025090703030493000_31.2.135.22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jchromb.2004.01.029","article-title":"Aggregation and denaturation of antibodies: a capillary electrophoresis, dynamic light scattering, and aqueous two-phase partitioning study","volume":"807","author":"Bermudez","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2025090703030493000_31.2.135.23","doi-asserted-by":"publisher","DOI":"10.1023\/B:PHAM.0000032993.98705.73"},{"key":"2025090703030493000_31.2.135.24","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1208\/s12248-013-9522-2","article-title":"Flow imaging microscopy for protein particle analysis--a comparative evaluation of four different analytical instruments","volume":"15","author":"Z\u00f6lls","year":"2013","journal-title":"AAPS J"},{"key":"2025090703030493000_31.2.135.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(99)00152-0"},{"key":"2025090703030493000_31.2.135.26","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0141-0229(01)00340-4","article-title":"Lysozyme inactivation under mechanical stirring: effect of physical and molecular interfaces","volume":"28","author":"Colombi\u00e9","year":"2001","journal-title":"Enzyme Microb Technol"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2021-003198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:03:15Z","timestamp":1757239395000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2021-003198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,22]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/ejhpharm-2021-003198"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2021-003198","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]}}}